SCHEDULE 13G/A: Point72 Asset Management Discloses Negligible Stake in Syros Pharmaceuticals
Beneficial Ownership Report
Point72 Asset Management, along with its affiliates and Steven A. Cohen, has filed an amended Schedule 13G disclosing a 0.0% beneficial ownership stake in Syros Pharmaceuticals, Inc. as of December 31, 2024.
Summary
- Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 496 shares of Syros Pharmaceuticals, Inc. common stock.
- This ownership represents 0.0% of Syros Pharmaceuticals, Inc.'s outstanding common stock as of December 31, 2024.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment purpose.
- The reporting persons maintain shared voting and dispositive power over the 496 shares.
- The shares are held by an investment fund managed by Point72 Asset Management, with Point72 Capital Advisors Inc. as its general partner, and Mr. Cohen controlling both entities.
Sentiment
Score: 5
Explanation: The document is a neutral, administrative filing disclosing a negligible beneficial ownership stake (0.0%). It provides no positive or negative operational or financial information about the issuer, Syros Pharmaceuticals, Inc., nor does it indicate any significant investment intent from the reporting parties.
Future Outlook
This document does not contain any forward-looking statements or guidance from Syros Pharmaceuticals, Inc. or the reporting entities regarding the issuer's future performance.
Industry Context
This filing is a routine disclosure by an institutional investment firm, Point72 Asset Management, regarding its passive, negligible stake in a biotechnology company. It reflects standard regulatory compliance for investment holdings rather than a strategic move or operational update for Syros Pharmaceuticals. Such small holdings are common among large asset managers and typically do not signal significant investment intent or industry trends.
Stakeholder Impact
- Shareholders: Minimal to no impact due to the negligible 0.0% ownership stake reported by Point72 Asset Management and its affiliates. This filing does not suggest any change in control or significant investment interest.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which required the filing of this statement, reflecting the beneficial ownership position. |
| 02/14/2025 | Date the Schedule 13G Amendment No. 1 was signed by Jason M. Colombo, Authorized Person for the reporting entities. |
Keywords
Syros Pharmaceuticals, Point72 Asset Management, Steven A. Cohen, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.